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ABSTRACT 
 
OBJECTIVE:  The objective of this selective EBM review is to determine whether or not 
magnetic stimulation is an effective treatment for women with urinary incontinence. 
 
STUDY DESIGN:  Review of three published, randomized controlled trials (two double-blind 
and one single blinded), all English language. 
 
DATA SOURCES:  The three randomized controlled trials that were used for this review were 
found using PubMed and EBSCOhost. Articles were selected based on relevance and that the 
outcomes of the studies mattered to patients. 
 
OUTCOME(S) MESURED:  Improvement of urinary incontinence measured by pad-tests and 
questionnaires. 
 
RESULTS: The results of the But study suggest that magnetic stimulation is not much more 
effective when compared to the control.  Gilling et al. demonstrated that there was a statistically 
significant improvement in the active arm at 8-wks for 20-min pad test, #pads/day, PFM 
strength, 24-h pad test, I-QOL and KHQ scores. Although p-values suggest improvement, 
comparing changes in each variable from baseline between groups using ANOVA showed no 
statistically significant difference in any outcome measure at 8 weeks or 6 months. Wallis et al. 
demonstrated that there were no statistically significant differences in the outcome measures 
between baseline and 12 weeks for the treatment and control groups. On the subjective measure 
there was a statistically significant difference between the active and control groups (p=0.04).  
 
CONCLUSIONS:  The results of these three randomized controlled trials suggest that magnetic 
stimulation is not much more effective than a placebo in the treatment of urinary incontinence. 
 
KEY WORDS:  Urinary incontinence, magnetic stimulation 
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INTRODUCTION 
Urinary incontinence (UI) is involuntary loss of urine.  UI is a common problem in older 
adults and there are three types of urinary incontinence:  stress, urge and overflow.  Stress 
incontinence is most common in women and results from increased intra-abdominal pressure.  
This paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of 
magnetic stimulation as a treatment for urinary incontinence. 
This topic/question is relevant to patients and PA practice because it is common, costly 
and accounts for a significant amount of healthcare visits each year.  The prevalence of urinary 
incontinence increases with age.  The prevalence of urinary incontinence in women ranges from 
25-51%.  Prevalence of UI in women in nursing homes is 60-78%. 30-60% of pregnant women 
report UI1.  $20 billion was spent on UI in 2000 and cost has nearly doubled in the past decade1.  
In 1998 there were 522,240 office visits with UI as primary diagnosis for female Medicare 
beneficiaries2. 
Continence depends upon both intact micturition physiology (including lower urinary 
tract, pelvic, and neurologic components) and an intact functional ability to toilet oneself. 
Successful toileting depends upon ready access to toilet facilities, the motivation to maintain 
dryness, sufficient mobility and manual dexterity, and the cognitive ability to recognize and react 
appropriately to sensations of bladder filling.  About 50% of affected women have stress 
incontinence, with mixed-stress and urge next common, followed by urge incontinence.  Stress 
incontinence is caused by inadequate pelvic support and decreased estrogen.  Urge incontinence 
is the most common form in older adults1. 
The usual methods of treatment are lifestyle modifications, behavioral therapy, adjunctive 
treatments, pharmacologic therapy, and surgery.  Lifestyle modifications include:  dietary 
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changes, monitoring fluid intake, avoiding caffeine and alcohol, smoking cessation, and weight 
loss.  Behavioral therapy consists of bladder training (frequent voiding, training of CNS and 
pelvic mechanisms to inhibit urgency) and pelvic muscle exercises to strengthen muscular 
urethral closure mechanism and biofeedback.  Adjunctive measures include:  pads, protective 
garments and pessaries.  Pharmacologic therapy available:  Antimuscarinics, Duloxetine, 
OnabotulinumtoxinA3. 
Magnetic stimulation devices are thought to stimulate pelvic muscle contractions and/or 
modulate detrusor contractions, which are necessary for urinary continence.  This method of 
treatment is being proposed because of the limited efficacy of current treatment modalities3. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not magnetic 
stimulation is an effective treatment for women with UI. 
METHODS 
The studies included are three randomized controlled trials (two double-blind and one 
single-blinded).  The population studied was women with urinary incontinence.  The intervention 
was magnetic stimulation.  Comparisons:  The treatment group receiving magnetic stimulation to 
the experimental group who received a placebo (non-functioning magnets).  Outcomes 
measured:  improvement of urinary incontinence measured by pad-tests and questionnaires. 
Key words used in the searches were “urinary incontinence” and “magnetic stimulation.”  
All articles were published in English and in peer-reviewed journals.  This author searched 
articles via PubMed and EBSCOhost.  The reviewed articles were selected based on relevance 
and that the outcomes of the studies mattered to patients (POEMs).  The inclusion criteria 
included:  women with urinary incontinence.  Exclusion criteria included:  implanted electronic 
Brandtonies, Magnetic Stimulation for UI   3	  
equipment, concurrent use of drugs to manage UI, pelvic floor surgery, and pregnancy.  
Summary statistics were reported using: p values, RBI, ABI, NNT. 
Table 1:  Demographics and Characteristics of included studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
criteria 
Exclusion 
criteria 
W/D Intervention 
But4 
(2003) 
Double-
blind 
RCT 
55 >18 
y/o 
Women with UI,  
>18 y/o, not 
pregnant, not 
physically or 
mentally 
disabled. 
Implanted electronic 
devices, urolithiasis, 
bladder infection, 
tumor, recent 
urethral/continence 
surgery; taking 
anticholinergics, BB 
or diuretics. 
3 Magnetic 
stimulation 
Gilling5 
(2009) 
Double-
blind 
RCT 
70 >20 
y/o 
Women >20 y/o, 
sxs of or 
confirmed UI, 
ambulatory, live 
home, 
neurologically 
normal, healthy, 
normal UA, 
stable detrusor 
function on 
urodynamics 
incontinence/pelvic 
floor surgery, grade 3 
or 4 pelvic prolapse, 
pregnancy, drugs for 
bladder dysfunction, 
internal  electronic 
medical devices, 
pelvic or lower limb 
metallic prosthesis 
15 Magnetic 
stimulation 
Wallis6 
(2012) 
Single-
blinded 
RCT 
122 >60 
y/o 
Women  >60 
y/o, live at 
home, UI 
symptoms Q 
week x 6 mos. 
implanted electronic 
device, symptomatic 
UTI, drugs for UTI 
last 4 weeks, 
scheduled for pelvic 
floor or GYN surgery 
within next 3 months 
21 Magnetic 
stimulation 
 
OUTCOMES MEASURED 
But study outcomes measured were:  urine frequency/loss, nocturia, and PFM 
contractions.  The outcomes were measured by:  number of pads used, pad weight, volume 
voided charts, power/duration of PFM contractions measured with perineometer, patient report 
by visual analog scale4. 
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Gilling et al Outcomes measured were reduction of urinary leakage and quality of life 
which were measured by: 3-day bladder diary, 20 min. provocative pad-test with predetermined 
bladder volume, and 24 hour pad test, incontinence quality of life questionnaire (I-QOL) scores, 
Kings Health Questionnaire (KHQ) scores, CMV score, peritron perineometry score, and PFX 
perineometry score5. 
Wallis et al. Outcomes measured were cessation of incontinence, frequency and severity 
of symptoms, which were measured by:  24-hour pad test, BFLUTS-SF, incontinence severity 
index, bothersomeness visual analog scale, and 24-hour bladder diary6. 
RESULTS 
 The three studies reviewed compared magnetic stimulation to a placebo.  All trials were 
completed in women with urinary incontinence. 
The But4 study was a randomized, double blind, placebo controlled trial that randomized 
55 subjects into an active group (30 patients) and placebo group (22 patients).  Each patient in 
the active group was given a Pulsegen device, which produced a pulsating magnetic field, to 
wear day and night for 2 months.  Of the 55 participants who entered the trial, 52 completed the 
study (5% loss to follow-up).  “Worst-case” analysis was not done on participants lost to follow 
up.  There was no statistically significant difference between the participants in the active and 
placebo groups as determined by the Mann-Whitney U test (P>0.05).  55.8 years was the average 
age of the women in the study, 40.4% had mixed incontinence, 42.3% has urge incontinence and 
17.3% had stress incontinence.   After 2 months of continuous magnetic stimulation with the 
Pulsegen device, the active group had a statistically significant decrease in daytime frequency 
(P=0.048), decrease in nocturia (P=0.0057), decrease in number of pads used (P=0.0031), 
decrease in pad weight (P=0.014), increased power of PFM (pelvic floor muscle contractions) 
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(P=0.0071), and length of PFM contractions (P=0.038).  The active group reported a 56.3% 
improvement in UI symptoms by a visual analog scale, which was statistically significant when 
compared to the placebo (P=0.00012).  The placebo group had a statistically significant decrease 
in nocturia (P=0.0035).  The placebo group reported a 26.3% improvement in symptoms by a 
visual analog scale.  79% (EER) of participants in active group and 22.7% (CER) of participants 
in placebo group evaluated success of magnetic stimulation as “excellent” or “good.”  The 
placebo had a statistically significant lower success rate than the active group (P=0.0022). Table 
2 shows the treatment effect of magnetic stimulation on urinary incontinence.  Relative benefit 
increase (RBI) was calculated to be a 2.48%.  Absolute benefit increase (ABI) was calculated to 
be 56.3%. Numbers needed to treat (NNT) was calculated as 2, indicating that 2 patients need to 
be treated to see one or more positive outcomes4. 
Table 2:  Treatment effect of Pulsegen magnetic stimulation on urinary incontinence 
CER EER RBI ABI NNT P 
22.7% 79% 2.48% 56.3% 2 0.0022 
 
 The Gilling5 et al. was also a double blind, randomized controlled trial that randomized 
35 women with urodynamically confirmed stress UI into either the active or sham groups.  The 
women in the active group were treated with the NeoControl chair and received 3 sessions per 
week for 6 weeks.  Of the 70 women who were enrolled in the study, only 55 completed (21.4% 
loss to follow-up).  “Worst case” analysis was not done on participants lost to follow-up.  The 
participants were evaluated at baseline, 8-weeks, and 6 months. The primary outcome measure 
was a change in the 20-minute pad test from baseline to 8-weeks. Table 3 shows the treatment 
effect of the NeoControl chair on SUI. In the active group there was a statistically significant 
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improvement at 8-weeks for the 20-minute pad test (p<0.001), number of pads used per day 
(p<0.01), PFM strength, 24-hour pad test (p<0.01), I-QOL (urinary incontinence quality of life 
scale) (p<0.001) and KHQ (kings health questionnaire) (p<0.001) scores.  In the placebo group 
there was a statistically significant improvement at 8-weeks for the 24-hour pad test and I-QOL 
score.  Statistical significance was defined as a 0.67 standard deviation difference in reduction 
between the groups.  17% (EER) of patients in the active group and 9% (CER) of patients in the 
placebo group did not leak on repeat urodynamics at 8-weeks.  RBI was calculated to be 0.89%.  
ABI was calculated to be 8%.  NNT was calculated as 135. 
Table 3:  Treatment effect of NeoControl chair on stress urinary incontinence 
CER EER RBI ABI NNT 
9% 17% 0.89% 8% 13 
 
 The study by Wallis6 et al. was a single blinded, randomized, placebo controlled trial of 
static magnetic stimulation on women aged 60 and older with UI for at least 6 months. 122 
subjects entered the trail and 101 completed the trial (17.2% loss to follow up).  “Worst case” 
analysis was not done on subjects lost to follow-up.  50 participants were randomly assigned to 
the active group and 51 to the placebo group.  The active group received an undergarment 
containing 15 static magnets that they were to wear at least 12 hours per day for 3 months.  The 
primary outcome was incontinence cessation measured by 24-hour pad test (P=0.09).  Frequency 
and severity of symptoms were the secondary outcomes, which were measured by BFLUTS-SF 
(Bristol Female Lower Urinary Tract Symptoms questionnaire) (P>0.05), Incontinence Severity 
Index (P=0.59), Bothersomeness Visual Analog scale (P=0.21) and 24-hour bladder diary 
(P>0.05).  Data was gathered at baseline and 12 weeks later.  Table 4 shows the treatment effect 
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of static magnetic stimulation on UI.  There were no statistically significant differences between 
the active and placebo groups in any of the measured outcomes from baseline to 12-weeks.  
However, the subjects that adhered to the protocol 85% of the time, the active group had a 
statistically significant decrease in the Bothersomeness score at 12-weeks (P=0.02).  RBI was 
calculated to be 0.57%.  ABI was calculated to be 20.5%.  NNT was calculated to be 56. 
Table 4:  Treatment effect of static magnetic stimulation on UI 
CER EER RBI ABI NNT 
36% 56.5% 0.57% 20.5% 5 
 
 There appears to be few adverse events and magnetic stimulation was generally well 
tolerated and safe in the three articles reviewed.  The But4 study reported that one patient 
experienced acute onset of pre-existent lumbar-ischialgia, which resolved with removal of the 
Pulsegen device.  Two other patients in the But4 study experienced a pulsating sensation in the 
lower abdomen and perineum. 
DISCUSSION 
 This selective evidence based medicine review investigated three randomized controlled 
trials to determine whether or not magnetic stimulation is an effective treatment for women with 
UI.  None of the studies selected provided definitive evidence that magnetic stimulation is an 
effective treatment modality for UI. 
 The results of the But4 study are generalizable to female patients with UI and suggest that 
magnetic stimulation with the Pulsegen may be a good conservative treatment for urinary 
incontinence. However, the RBI of 2.48% is small and suggests that the treatment is not much 
more effective when compared to the placebo.  ABI suggests that 56.3% of patients will have 
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improvement of urinary incontinence symptoms if they use magnetic stimulation instead of 
nothing.  Some limitations of the study include:  patient compliance, small sample size, unequal 
distribution between active and placebo groups, and inability of study to determine the rate of the 
placebo effect4. 
 The results of the Gilling et al. study are generalizable to women with UI described in my 
clinical question. Although p-values suggest statistically significant improvement of UI with 
NeoControl chair, comparing changes in each variable from baseline between groups using 
ANOVA showed no statistically significant difference in any outcome measure at 8 weeks or 6 
months. Calculated RBI of 0.89% and ABI of 8% are small values and suggest that the treatment 
is not more effective when compared to placebo.  Some limitations of the study include:  small 
sample size, 21.4% loss to follow-up, unforeseen effects of pelvic floor muscle training5. 
 The results of the Wallis et al. study are generalizable to women with UI. There were no 
statistically significant differences in the outcome measures between baseline and 12 weeks for 
the treatment and control groups. On the subjective measure (when patients were asked at the 
end of study whether their UI had improved) there was a statistically significant difference 
between the active and control groups (p=0.04).  However, once sensitivity analysis was done, 
the benefit was no longer statistically significant.  The calculated RBI of 0.57% and ABI of 
20.5% are small and suggest that the treatment is not more effective when compared to placebo.  
Some limitations of the study include:  poor patient compliance because of garment issues 
(uncomfortable, visible under clothing), placebo effect, and difficulty blinding because the 
magnets attracted metal objects6. 
CONCLUSIONS 
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 In theory, magnetic stimulation appears to be a promising treatment modality for UI.  
However, based on the results of reviewed studies, magnetic stimulation does not appear to be an 
effective treatment modality for UI.  Statistical significance was only attained by the But4 study, 
which did not perform sensitivity analysis to rule out placebo effect.  I can therefore conclude 
that the reviewed studies demonstrated no definitive evidence that magnetic stimulation is an 
effective treatment for UI.  Due to the pervasiveness of UI in women, future study of non-
invasive treatments such as magnetic stimulation for treatment is warranted. 
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